• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2022 Jun 24;S1201-9712(22)00373-3.
doi: 10.1016/j.ijid.2022.06.039. Online ahead of print.
Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data


Yosuke Hirotsu[SUP] 1 [/SUP], Makoto Maejima[SUP] 2 [/SUP], Masahiro Shibusawa[SUP] 2 [/SUP], Yume Natori[SUP] 2 [/SUP], Yuki Nagakubo[SUP] 3 [/SUP], Kazuhiro Hosaka[SUP] 2 [/SUP], Hitomi Sueki[SUP] 2 [/SUP], Hitoshi Mochizuki[SUP] 4 [/SUP], Toshiharu Tsutsui[SUP] 5 [/SUP], Yumiko Kakizaki[SUP] 5 [/SUP], Yoshihiro Miyashita[SUP] 5 [/SUP], Masao Omata[SUP] 6 [/SUP]



Affiliations

Abstract

Objective: Recently, the Omicron strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread and replaced the previously dominant Delta strain. Several Omicron sublineages (BA.1, BA.1.1 and BA.2) have been identified, with in vitro and preclinical reports showing that the pathogenicity and therapeutic efficacy differs between BA.1 and BA.2. We sought to develop a TaqMan assay to identify these subvariants.
Methods: A TaqMan assay was constructed for rapid identification and genotyping of Omicron sublineages with 171 samples. We analyzed three characteristic mutations of the spike gene, Δ69-70, G339D and Q493R, by TaqMan assay. The accuracy of the TaqMan assay was examined by comparing its results with the results of whole genome sequencing (WGS) analysis.
Results: A total of 171 SARS-CoV-2 positive samples were analyzed by WGS and TaqMan assay. The 127 samples determined as BA.1/BA.1.1 by WGS were all positive for Δ69-70, G339D and Q493R by TaqMan assay. Forty-two samples determined as BA.2 by WGS were negative for Δ69-70 but positive for G339D and Q493R by TaqMan. Two samples with G339N were determined to be inconclusive by the TaqMan method. Except for these two samples, the concordance rate between WGS and the TaqMan assay was 100% (169/169).
Conclusion: TaqMan assays targeting characteristic mutations are useful for identification and discrimination of Omicron sublineages.

Keywords: BA.1; BA.2; Omicron; SARS-CoV-2; VOC.
 
Back
Top Bottom